Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research Accomplishments in Pulmonary, Critical Care, and Sleep: A Retrospective Review.

American journal of respiratory and critical care medicine·2023
Same author

The intersection of women's health, lung health, and disease.

American journal of physiology. Lung cellular and molecular physiology·2021
Same author

Diagnosing and treating lung disease at the cellular level.

American journal of physiology. Lung cellular and molecular physiology·2020
Same author

Precision Health Analytics With Predictive Analytics and Implementation Research: JACC State-of-the-Art Review.

Journal of the American College of Cardiology·2020
Same author

A Perspective: Division of Lung Diseases at Fifty.

American journal of respiratory and critical care medicine·2019
Same author

Fifty Years of the Division of Lung Diseases: A Program Officer Perspective.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2019

Related Experiment Videos

Challenges associated with estimating minimal clinically important differences in COPD-the NHLBI perspective.

James P Kiley1, J Sri Ram, Thomas L Croxton

  • 1Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Suite 10018, 6701 Rockledge Drive, Bethesda, Maryland 20892, USA. KileyJ@nih.gov

COPD
|December 2, 2006
PubMed
Summary

Defining minimal clinically important differences (MCID) for Chronic Obstructive Pulmonary Disease (COPD) is challenging due to patient heterogeneity and symptom exacerbations. Further research is needed for meaningful MCIDs in COPD clinical trials.

Related Experiment Videos

Area of Science:

  • Pulmonary Medicine
  • Clinical Research Methodology

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) research faces challenges in defining meaningful clinical endpoints.
  • Minimal Clinically Important Differences (MCID) are valuable but difficult to establish for COPD.

Purpose of the Study:

  • To explore the complexities and challenges of developing and validating MCIDs for COPD clinical research.
  • To highlight the need for consensus on MCIDs in COPD therapeutic trials.

Main Methods:

  • Review of existing literature and challenges in COPD endpoint development.
  • Analysis of factors complicating MCID validation in heterogeneous COPD populations.

Main Results:

  • Patient heterogeneity, genetic factors, and acute exacerbations complicate MCID definition in COPD.
  • The National Heart, Lung, and Blood Institute (NHLBI) does not mandate MCIDs for COPD research, allowing flexibility in endpoint selection.

Conclusions:

  • Standardizing MCIDs is crucial for advancing COPD research and improving public health outcomes.
  • Further investigation into MCID concepts and applications is essential for effective COPD therapeutic trials.